Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: J Immunol. 2011 Feb 11;186(6):3674–3685. doi: 10.4049/jimmunol.1003037

Figure 6. Switching tocopherol isoforms at supplemental levels in phase 2 did not alter OVA-specific IgE, lung cytokines or lung chemokines.

Figure 6

Mice were treated with supplemental levels of tocopherols as in Figure 3A. A. serum OVA-specific IgE as measured by ELISA. B-F,I,J. BAL supernatants were examined for cytokines using the Th1/Th2 mouse cytokine multiplexing kit with IL-13 (Life Technologies). G,H. lung tissue was placed in RNAlater then examined for eotaxin 1 (CCL11) and eotaxin 2 (CCL24) expression by real-time PCR. veh OVA→veh OVA group, indicates phase 1 treatments followed by phase 2 treatments as described in Figure 3A; veh, vehicle; αT, d-alpha-tocopherol; γT, d-gamma-tocopherol; *, p<0.05 as compared to veh OVA→veh OVA group.